Biointron is proud to share that we have received the 2024 Scientist.com Supplier Performance Recognition Award, for our dedication to providing high-quality drug discovery research services on this industry-renowned R&D sourcing platform.

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules designed to degrade specific proteins by recruiting an E3 ubiquitin ligase to the target protein, leading to its ubiquitylation and subsequent degradation by the proteasome. This novel mechanism enables PROTACs to eliminate on

Biointronは2012年に設立され、ISO 9001:2015認証を取得した、世界中のバイオテクノロジーおよび製薬企業向けに抗体探索、最適化、発現サービスを提供するリーディングCRO（契約研究機関）です。10年以上の経験を活かします。

According to Research and Markets, the global market for Fc and glycoengineered antibodies is projected to be worth US$38.8 billion in 2024. Over the next decade, the growth in opportunities for drug developers is expected to be driven by an increasing patient population and rising demand for these

Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected mosquitoes. Of the five species of Plasmodium that cause malaria, Plasmodium falciparum is the deadliest, responsible for the majority of cases and deaths, particularly in Africa, where young children are

Alzheimer’s research has undergone transformative changes in recent years, characterized by breakthroughs, controversies, and a reevaluation of long-held theories. Recently, BioArctic announced a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-

抗体研究を加速するためには、高品質な抗体やタンパク質へのアクセス、効率的な生産スケジュール、信頼できるパートナーシップが不可欠です。抗体の探索、発現、最適化を専門とするリーディングCRO（契約研究機関）であるBiointronは、こうしたニーズに応える信頼できる選択肢として、多くの企業に支持されています。

The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which

カスタム抗体の開発は、研究および治療革新の推進において重要な要素です。抗体発現サービスを専門とする契約研究機関（CRO）であるBiointronは、抗体生産のニーズに対して信頼性が高く、スケーラブルで高品質なソリューションを求めるバイオテック企業に包括的なサポートを提供します。

Antibody drugs offer targeted and effective therapies for inflammatory conditions such as chronic diseases like rheumatoid arthritis, Crohn's disease, and psoriasis. By specifically binding to pro-inflammatory cytokines or their receptors, monoclonal antibodies help modulate the immune response,

Biparatopic antibodies (bpAbs) are bispecific antibodies which bind distinct, non-overlapping epitopes on an antigen. This unique binding mode allows for superior affinity and specificity, promotes antagonism, locks target conformation, and results in higher-order target clustering. The antibody-target complexes can elicit strong agonism, increase immune effector function, or result in rapid target downregulation and lysosomal trafficking.

As antibody-drug development accelerates, ensuring consistent binding affinity, stability, and specificity is critical to improving treatment outcomes. Recent advances in antibody sequencing, artificial intelligence, and high-throughput screening have bolstered efforts to produce reliable antibody candidates more efficiently.

This month, two high-profile deals for bispecific antibodies targeting the PD-1/PD-L1 and VEGF pathways were announced. The DealsOn November 14, Merck announced its licensing agreement with LaNova Medicines for LM-299, an investigational PD-1/VEGF bispecific antibody. Merck is committing up to

Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory infections, particularly in infants, the elderly, and immunocompromised individuals. Despite its global prevalence, there has historically been a lack of effective therapeutic options for high-risk populations.

Discover the latest insights on antibody drug reliability, addressing aggregation, impurities, and stability challenges in biomedical research for improved outcomes.